Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Chronic Hepatitis C Virus (HCV Infection Genotype 1)

Interventions

DRUG

ombitasvir/paritaprevir/ritonavir, dasabuvir

tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

DRUG

sofosbuvir (SOF)

tablet

DRUG

ribavirin (RBV)

tablet